publication date: Apr. 3, 2020

NCI Trials

NCI Trials for April 2020

The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. 

For further information, contact the principal investigator listed.

 

Phase I – 10329

Phase I Sequential Trial of Agents Against DNA Repair (STAR)

University of Texas MD Anderson Cancer Center LAO

Yap, Timothy Anthony

(713) 563-1784

 

Phase I – PBTC-056

A Phase I Study of the ADAM-10 Inhibitor, INCB7839 in Children with Recurrent/Progressive High-Grade Gliomas to Target Microenvironmental Neuroligin-3

Pediatric Brain Tumor Consortium

Monje, Michelle

(650) 736-0885

 

Phase I/II – 10221

A Phase I/II Biomarker Driven Combination Trial of Copanlisib and Immune Checkpoint Inhibitors in Patients with Advanced Solid Tumors

University of Texas MD Anderson Cancer Center LAO

Yap, Timothy Anthony

(713) 563-1784

 

Phase II – 10264

The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. A Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Yale University Cancer Center LAO

Prebet, Thomas

(203) 737-7103

 

Phase II – ADVL18P1

An Open-Label Feasibility Study to Assess the Safety and Pharmacokinetics of Enasidenib in Pediatric Patients with Relapsed/Refractory Acute Myeloid Leukemia (R/R-AML) with an Isocitrate Dehydrogenase-2 (IDH2) Mutation

Children’s Oncology Group

Zarnegar-Lumley, Sara

(615) 936-1762

 

Phase II – APEC1621K

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients with Tumors Harboring IDH1 Mutations

Children’s Oncology Group

Alva, Elizabeth Duncan

(205) 638-9285

 

Phase III – AAML1831

A Phase 3 Randomized Trial for Patients with De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations

Children’s Oncology Group

Cooper, Todd Michael

(206) 987-2106

 

Phase III – S1914

A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC

SWOG

Daly, Megan Eileen

(916) 734-5428

Copyright (c) 2020 The Cancer Letter Inc.